secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001104659-25-048502
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway
----------------------------------------------------------------------------

- Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.
- Revenue $13.1M, flat YoY; includes $2.1M from Emrosi launch.
- Gross margin improved to 64% from 54% YoY; R&D costs nil vs $7.9M.
- Cash $21.1M at March 31, 2025 (vs $20.3M at Dec 31, 2024).
- Emrosi commercial launch started April 7; Phase 3 results published in JAMA Dermatology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/0001104659-25-048502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/tm2514979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-048502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer